This move is archived. Current quotes and coverage live on the stock page.
Get MSCL alerts:
Satellos Bioscience Inc. (MSCL.TO) has surged by over 21% in just one trading day, marking a significant milestone for the company.
In a remarkable turn of events, Satellos Bioscience Inc. saw its stock price soar by 21.31% in the latest trading session, closing at CA$9.62. This surge has captured the attention of investors eager to understand the driving forces behind this impressive rally.
Investor takeaway: For Canadian investors, the rapid rise of Satellos Bioscience Inc. signals potential opportunities in the biotech sector, particularly for companies focused on innovative treatments for rare diseases.
Advertisement
Satellos Bioscience Inc.
MSCL.TO
MSCL.TO
Satellos Bioscience Inc.
WealthAwesomeMarket cap
$272.63M
52W high
$18.98
52W low
$7.32
1W change
-3.67%
Beta
1.17
Analyst Price Targets
Based on analyst covering MSCL
Wall Street analysts forecast MSCL stock price to rise 40.2% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$17.67
+40.2% Upside
Current Price
C$12.60
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MSCL's historical volatility
30-Day Vol
61.6%
Annualized
90-Day Vol
74.7%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$15.06
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$13.37 | C$10.81 โ C$16.54 |
| 60 trading days | C$14.19 | C$10.51 โ C$19.17 |
| 90 trading days | C$15.06 | C$10.43 โ C$21.77 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Satellos Bioscience Inc. Stock Jumps 21.31% in One Day
Advertisement
With a market cap of CA$165 million, Satellos is gaining traction as it progresses through critical clinical trials.
Bull case
The strong performance reflects investor optimism about the company's ongoing clinical trials and recent advancements in their product pipeline, especially the SAT-3247 treatment for Duchenne muscular dystrophy. Investors are hopeful that these developments will lead to positive outcomes and enhance the company's market position.
Bear case
However, investors should stay cautious. The biotech sector can be unpredictable, and the lack of recent news might mean that the stock's rise is more about speculation than solid fundamentals.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile โโ Reviewed by Certified Financial Professionals
This content has been reviewed by CFAยฎ charterholders and Certified Financial Planners (CFPยฎ) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFAยฎ charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFPยฎ professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
โ ๏ธ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
